Oleogel-S10

Phase 3Small molecule

Chiesi Farmaceutici S.p.A.

Oleogel-S10 is one of 12 small molecule programs targeting Epidermolysis Bullosa. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epidermolysis BullosaRecruiting

Epidermolysis BullosaPhase 3

Recruiting

Competition

Competitive Landscape

11 competitors in Epidermolysis Bullosa

#DrugCompanyPhaseTrials

Fludara

Busulfex

1 3

Cytoxan

BBaxter Healthcare Corporation

Approved

1 4

Accutane

CConrado Roberto Hoffmann Filho

Approved

—5

E-Mycin

AAzurity Pharmaceuticals

Approved

—6

Oleogel-S10

Chiesi Farmaceutici S.p.A.

Phase 3

2 7

Allo-APZ2-OTS

RRHEACELL GmbH & Co. KG

Phase 3

2 8

Fludara

Sanofi

Preclinical

1 9

Garamycin

SSchering-Plough

Phase 2

1 10

Naropin

FFresenius Kabi USA, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Recruiting

Epidermolysis Bullosa

NCT06917690

Clinical

Trials by Indication[1]

Epidermolysis Bullosa2 trials

A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

Recruiting· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 3·NCT06917690·6 enrolled

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

Completed·AAmryt Research Limited·Phase 3·NCT03068780·223 enrolled

Actinic Keratoses1 trial

The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses

Completed·BBirken AG·Phase 2·NCT00786994·165 enrolled

Wound Healing1 trial

Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites

Completed·BBirken AG·Phase 2·NCT01294254·24 enrolled

Burn Wounds1 trial

Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds

Completed·BBirken AG·Phase 3·NCT01657292·61 enrolled

Breast Cancer1 trial

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05190770·18 enrolled

1 more indication

Inherited Epidermolysis Bullosa1 trial

Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)

Completed·BBirken AG·Phase 2·NCT01294241·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Oleogel-S10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oleogel-S10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oleogel-S10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Chiesi Farmaceutici S.p.A.

Oleogel-S10

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Epidermolysis Bullosa2 trials

Actinic Keratoses1 trial

Wound Healing1 trial

Burn Wounds1 trial

Breast Cancer1 trial

Inherited Epidermolysis Bullosa1 trial

References

Drug Info

Quick Facts

Related News